Revenue (Tables)

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:

	Three Months Ended September 30,				Nine Months Ended September 30,
Revenue by product (in thousands)	2025		2024		2025		2024
MACI implants, kits, and instruments
Implants based on contracted rate sold through a specialty pharmacy (a)	$	41,090	$	31,637	$	113,086	$	90,246
Implants subject to third party reimbursement sold through a specialty pharmacy (b)	4,034		3,473		9,605		10,160
Implants sold direct based on contracted rates (c)	8,032		6,968		25,358		21,465
Implants sold direct subject to third-party reimbursement (d)	1,056		1,083		3,624		3,227
Biopsy kits and instruments - direct bill	652		469		1,890		1,530
Change in estimates related to prior periods (e)	798		1,026		1,853		2,345
Total MACI implants, kits, and instruments	55,662		44,656		155,416		128,973
Epicel
Direct bill (hospital)	10,375		12,184		23,954		30,606
NexoBrid	1,466		1,065		3,971		2,269
Total revenue	$	67,503	$	57,905	$	183,341	$	161,848
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.